Market closed
Lineage Cell Therapeutics/$LCTX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Lineage Cell Therapeutics
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Ticker
$LCTX
Sector
Trading on
AMEX
Industry
Biotechnology
Headquarters
Employees
72
Website
LCTX Metrics
BasicAdvanced
$133M
-
-$0.11
1.28
-
Price and volume
Market cap
$133M
Beta
1.28
52-week high
$1.61
52-week low
$0.48
Average daily volume
2.3M
Financial strength
Current ratio
2.481
Quick ratio
2.389
Long term debt to equity
2.489
Total debt to equity
4.244
Management effectiveness
Return on assets (TTM)
-11.84%
Return on equity (TTM)
-30.50%
Valuation
Price to revenue (TTM)
12.708
Price to book
1.72
Price to tangible book (TTM)
12.68
Price to free cash flow (TTM)
-4.806
Growth
Revenue change (TTM)
-0.60%
Earnings per share change (TTM)
-18.73%
3-year revenue growth (CAGR)
35.20%
3-year earnings per share growth (CAGR)
10.84%
What the Analysts think about LCTX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Lineage Cell Therapeutics stock.
LCTX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
LCTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
LCTX News
AllArticlesVideos
Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering
Business Wire·3 days ago
Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering
Business Wire·2 months ago
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2024 Earnings Call Transcript
Seeking Alpha·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Lineage Cell Therapeutics stock?
Lineage Cell Therapeutics (LCTX) has a market cap of $133M as of January 31, 2025.
What is the P/E ratio for Lineage Cell Therapeutics stock?
The price to earnings (P/E) ratio for Lineage Cell Therapeutics (LCTX) stock is 0 as of January 31, 2025.
Does Lineage Cell Therapeutics stock pay dividends?
No, Lineage Cell Therapeutics (LCTX) stock does not pay dividends to its shareholders as of January 31, 2025.
When is the next Lineage Cell Therapeutics dividend payment date?
Lineage Cell Therapeutics (LCTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Lineage Cell Therapeutics?
Lineage Cell Therapeutics (LCTX) has a beta rating of 1.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.